Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Cell Source, Inc. is a biotech company specializing in immunotherapy and cell therapy technologies. It develops proprietary immune management platforms, including Veto Cell and Veto CAR-T, to improve transplantation safety, reduce rejection, GvHD, and infections. Focused on blood cancers, organ failure, and autoimmune diseases, it licenses patents from Yeda Research and collaborates with MD Anderson to advance off-the-shelf, allogeneic treatments for broader patient access and improved outcomes.
This description was generated via AI from an annual report. Updated about 1 year ago.